{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:09:00Z","timestamp":1761494940226,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tiziana Pharmaceuticals"},{"name":"Kaneka Corporation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clim.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T04:30:56Z","timestamp":1500611456000},"page":"240-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice"],"prefix":"10.1016","volume":"183","author":[{"given":"Mineko","family":"Ogura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Preston-Hurlburt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunwar","family":"Shailubhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5610-4795","authenticated-orcid":false,"given":"Chantal","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevan C.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2017.07.005_bb0005","first-page":"175","article-title":"Anti-CD3 antibodies","volume":"59","author":"Chatenoud","year":"1993","journal-title":"Immunol. Ser."},{"key":"10.1016\/j.clim.2017.07.005_bb0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2013.05.001","article-title":"Anti-CD3 clinical trials in type 1 diabetes mellitus","volume":"149","author":"Daifotis","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2017.07.005_bb0015","first-page":"1907","article-title":"Modified anti-CD3 therapy in psoriatic arthritis: a phase I\/II clinical trial","volume":"29","author":"Utset TO","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2017.07.005_bb0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ibd.21084","article-title":"Prospective randomized open-label multicenter phase I\/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis","volume":"16","author":"Baumgart","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clim.2017.07.005_bb0025","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2007.08.035","article-title":"A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis","volume":"133","author":"Plevy","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clim.2017.07.005_bb0030","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2009.205443","article-title":"Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis","volume":"59","author":"Sandborn","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.clim.2017.07.005_bb0035","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00007890-199909150-00003","article-title":"Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection","volume":"68","author":"Woodle","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2017.07.005_bb0040","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.07.005_bb0045","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.clim.2017.07.005_bb0050","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2017.07.005_bb0055","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nm924","article-title":"TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes","volume":"9","author":"Belghith","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2017.07.005_bb0060","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1073\/pnas.0701171104","article-title":"Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment","volume":"104","author":"You","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2017.07.005_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partially exhausted CD8 T cells are associated with clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.clim.2017.07.005_bb0070","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI23961","article-title":"TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs","volume":"115","author":"Bisikirska","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2017.07.005_bb0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10228","article-title":"Control of TH17 cells occurs in the small intestine","volume":"475","author":"Esplugues","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clim.2017.07.005_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003401","article-title":"Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients","volume":"4","author":"Waldron-Lynch","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2017.07.005_bb0085","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nm1408","article-title":"Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25\u2212 LAP+ T cells","volume":"12","author":"Ochi","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2017.07.005_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2008.07.027","article-title":"New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity","volume":"274","author":"Ochi","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clim.2017.07.005_bb0095","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2337\/db06-1632","article-title":"Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody","volume":"56","author":"Ishikawa","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.clim.2017.07.005_bb0100","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.4049\/jimmunol.167.8.4245","article-title":"Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration","volume":"167","author":"Zhang","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.07.005_bb0105","doi-asserted-by":"crossref","first-page":"9765","DOI":"10.1073\/pnas.0908771107","article-title":"Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob\/ob mice","volume":"107","author":"Ilan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2017.07.005_bb0110","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2337\/db12-1175","article-title":"Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes","volume":"62","author":"Hu","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clim.2017.07.005_bb0115","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10875-015-0160-6","article-title":"Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial","volume":"35","author":"Lalazar","year":"2015","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2017.07.005_bb0120","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4049\/jimmunol.1103067","article-title":"Ecto-nucleoside triphosphate diphosphohydrolase 7 controls Th17 cell responses through regulation of luminal ATP in the small intestine","volume":"190","author":"Kusu","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.07.005_bb0125","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1111\/j.1600-6143.2012.04178.x","article-title":"Analysis of human biologics with a mouse skin transplant model in humanized mice","volume":"12","author":"Waldron-Lynch","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.clim.2017.07.005_bb0130","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clim.2017.07.005_bb0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00125-012-2753-4","article-title":"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial","volume":"56","author":"Herold","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.clim.2017.07.005_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaut.2016.10.001","article-title":"Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain","volume":"76","author":"Kuhn","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2017.07.005_bb0145","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1172\/JCI60530","article-title":"Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice","volume":"122","author":"Takiishi","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2017.07.005_bb0150","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.4049\/jimmunol.1100394","article-title":"Human natural regulatory T cell development, suppressive function, and postthymic maturation in a humanized mouse model","volume":"187","author":"Onoe","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.07.005_bb0155","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4049\/jimmunol.1302455","article-title":"Humanized mice as a model for aberrant responses in human T cell immunotherapy","volume":"193","author":"Vudattu","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2017.07.005_bb0160","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clim.2017.07.005_bb0165","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/00007890-199212000-00011","article-title":"Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome","volume":"54","author":"Charpentier","year":"1992","journal-title":"Transplantation"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161730342X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166161730342X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:00:28Z","timestamp":1761494428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166161730342X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":33,"alternative-id":["S152166161730342X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2017.07.005","relation":{},"ISSN":["1521-6616"],"issn-type":[{"type":"print","value":"1521-6616"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}